高水平氨基糖苷类耐药肠球菌体外耐药监测

Antimicrobial resistance status of high-level aminoglycoside resistance strains to enterococcus

目的了解肠球菌的分布和高水平氨基糖苷类耐药肠球菌(HLAR)的耐药现状,为临床合理用药提供依据。方法鉴定采用API鉴定系统,抗生素敏感试验采用Kirby-Bauer纸片扩散法。结果2005年1月至2007年9月检出肠球菌292株,43.1%来源于尿液标本;粪肠球菌占65.3%,屎肠球菌占30.1%,HLAR检出率占80.5%。粪肠球菌和屎肠球菌、HLAR和非HLAR的耐药性均不同。结论加强肠球菌的鉴定和HLAR的检测,有利于临床根据体外药敏试验结果选择用药。

Objective To investigate the distribution and antimicrobial resistance status of high-level aminoglycoside resistance （HLAR） in Shanghai Seamen＇s Hospital, so as to provide basis for rational therapy. Methods API Expression Identification System was adopted to perform bacteria identification. Antimicrobial susceptibility test was performed by Kirby-Bauer disk diffusion method. Results Of 292 clinical enterococcus isolates during Jan 2005- Sep 2007, 43.1% was from urine, and the isolates of E. faecalis and E. faecium accounted for 65.3% and 30.1% respectively. The detective rate of HLAR accounted for 80.5%. The antimicrobial resistance of E. faecalis was different from that of E. faecium, and so did HLAR and non-HLAR. Conclusion The detection of enterococcus and HLAR must be stressed. Antibiotics should be chosen rationally according to the results of antimicrobial susceptibility test.